Kardigan, Inc.
NASDAQ:KARDBiotechnology
+$0.77 today
- Market cap
- $1.10B
- Beta
- 0.00
Volume 0.55M
Average 5.84M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Kardigan, Inc.
NASDAQ:KARD
Intrinsic Alpha fair value
Locked
Current Price
$12.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
No data available for this stock.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Cytokinetics, Incorporated NASDAQ:CYTK | $7.82B | $56.13 | Not rated | -11.6 | -20.79% |
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | $2.42B | $20.14 | Not rated | -17.2 | -48.89% |
Inhibikase Therapeutics, Inc. NASDAQ:IKT | $213.21M | $1.52 | Not rated | -3.4 | -11.54% |
Atrium Therapeutics, Inc. NASDAQ:RNA | $128.46M | $7.51 | Not rated | -3.3 | — |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $79.59M | $0.35 | Not rated | -1.3 | -74.21% |
Continue the stock analysis
Jump to another research area for this company.